Custom-compounded bioidentical hormone therapy: why so popular despite potential harm? The case against routine use

References

• WHI Writing Group. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Panay N, Fenton A. Bioidentical hormones: what is all the hype about? Climacteric 2010;13:1–3
   PubMed Web of Science ®Google Scholar
• Roberts H, Lethaby A. Phytoestrogens for menopausal vasomotor symptoms: a Cochrane review summary. Maturitas 2014;78:79–81
   PubMed Web of Science ®Google Scholar
• Fenton A, Panay N. Menopause: quantifying the cost of symptoms. Climacteric 2013;16:405–6
   PubMed Web of Science ®Google Scholar
• Sarrel P, Njike V, Vinante V, Katz D. Mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years. Am J Public Health 2013;103:1583–8
   PubMed Web of Science ®Google Scholar
• Crandall CJ, Aragaki A, Cauley JA, et al. Associations of menopausal vasomotor symptoms with fracture incidence. J Clin Endocrinol Metab 2015;100:524–34
   PubMed Web of Science ®Google Scholar
• Zhu L, Jiang X, Sun Y, Shu W. Effect of hormone therapy on the risk of bone fractures: a systematic review and meta-analysis of randomized controlled trials. Menopause 2015;23:461–70
   Web of Science ®Google Scholar
• Gass MLS, Stuenkel CA, Utian WH, LaCroix A, Liu JH, Shifren JL. Use of compounded hormone therapy in the United States: report of the North American Menopause Society Survey. Menopause 2015;22:1276–84
   PubMed Web of Science ®Google Scholar
• Siyam T, Yuksel N. Beliefs about bioidentical hormone therapy: a cross-sectional survey of pharmacists. Maturitas 2013;74:196–202
   PubMed Web of Science ®Google Scholar
• Files JA, Kransdorf LN, Ko M, et al. Bioidentical hormone therapy: an assessment of provider knowledge. Maturitas 2016;94:46–51
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Santoro N. Compounded bioidentical menopausal hormone therapy: identifying use trends and knowledge gaps among US women. Menopause 2015;22:926–36
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Constantine GD. Compounded non-FDA-approved menopausal hormone therapy prescriptions have increased: results of a pharmacy survey. Menopause 2016;23:359–67
   PubMed Web of Science ®Google Scholar
• L’Hermite M, Simoncini T, Fuller S, Genazzani AR. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. Maturitas 2008;60:185–201
   PubMed Web of Science ®Google Scholar
• L’Hermite M. HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT. Climacteric 2013;16(Suppl 1):44–53
   PubMed Web of Science ®Google Scholar
• Mohammed K, Murad MH. Response to the Letter: “Transdermal vs oral estrogen therapy and venous thromboembolism: upgrade the level of evidence” by Scarabin MC, et al. J Clin Endocrinol Metab 2016;101:L32
   PubMedGoogle Scholar
• Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95(Suppl 1):S1–S66
   PubMed Web of Science ®Google Scholar
• Shapiro S. Risk of breast cancer among users of estrogen plus progestogen and unopposed estrogen: is the likelihood of bias symmetrical? Climacteric 2015;18:333–5
   PubMed Web of Science ®Google Scholar
• Shapiro S, Farmer RDT, Mueck AO, Seaman H, Stevenson JC. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: part 2. The Women’s Health Initiative: estrogen plus progestogen. J Fam Plann Reprod Health Care 2011;37:165–72
   PubMed Web of Science ®Google Scholar
• Shapiro S, de Villiers TJ, Pines A, et al. Risks and benefits of hormone therapy: has medical dogma now been overturned? Climacteric 2014;17:215–22
   PubMed Web of Science ®Google Scholar
• Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015;100:3975–4011
   PubMed Web of Science ®Google Scholar
• Baber RJ, Panay N, Fenton A. and the IMS Working Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016;19:109–50
   PubMed Web of Science ®Google Scholar
• Manson JE, Kaunitz AM. Menopause management: getting clinical care back on track. N Engl J Med 2016;374:803–6
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–78
   PubMed Web of Science ®Google Scholar
• Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. Br Med J 2012;345:e6409
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med 2016;374:1221–31
   PubMed Web of Science ®Google Scholar
• Boardman H, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Libr 2015;3:1–160
   Google Scholar
• Salpeter SR, Cheng J, Thabane L, Buckley NS, Salpeter EE. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med 2009;122:1016–22
   PubMed Web of Science ®Google Scholar
• Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause 2014;21:924–32
   PubMed Web of Science ®Google Scholar
• ACOG Committee Opinion No 556. Hormone therapy and heart disease. Obstet Gynecol 2013;565:1407–10
   Google Scholar
• Gass MLS, Maki PM, Shifren JL, et al. NAMS supports judicious use of systemic hormone therapy for women aged 65 years and older. Menopause 2015;22:685–6
   PubMed Web of Science ®Google Scholar
• Karim R, Dell RM, Greene DF, Mack WJ, Gallagher JC, Hodis HN. Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause 2011;18:1172–7
   PubMed Web of Science ®Google Scholar
• Mikkola TS, Tuomikoski P, Lyytinen H, et al. Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy. J Clin Endocrinol Metab 2015;100:4588–94
   PubMed Web of Science ®Google Scholar
• Pines A. Withdrawal of hormone therapy and increased risk of cardiovascular disease. Climacteric 2016;19:249–51
   PubMed Web of Science ®Google Scholar
• Mikkola TS, Tuomikoski P, Lyytinen H, et al. Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. Menopause 2015;22:976–83
   PubMed Web of Science ®Google Scholar
• Smith RM, Schaefer MK, Kainer MA, et al. Fungal infections associated with contaminated methylprednisolone injections. N Engl J Med 2013;369:1598–609
   PubMed Web of Science ®Google Scholar
• Chiller TM, Roy M, Nguyen D, et al. Clinical findings for fungal infections caused by methylprednisolone injections. N Engl J Med 2013;369:1610–19
   PubMed Web of Science ®Google Scholar
• Nortier J, Muniz Martinez M-C, Schmeiser H, et al. Urothelial carcinoma associated with the use of a chinese herb (Aristolochia Fangchi). N Engl J Med 2000;342:1686–92
   PubMed Web of Science ®Google Scholar
• Debelle FD, Vanherweghem J-L, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int 2008;74:158–69
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Pickar JH. Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy. Menopause 2016;23:215–23
   PubMed Web of Science ®Google Scholar
• Simon JA. The Woman’s Health Initiative and one of many unintended consequences. Menopause 2016;23:1057–9
   PubMed Web of Science ®Google Scholar
• Lacey JV, Brinton LA, Lubin JH, Sherman ME, Schatzkin A, Schairer C. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev 2005;14:1724–31
   PubMed Web of Science ®Google Scholar
• Roberts H, Hickey M, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia: a Cochrane review summary. Maturitas 2014;77:4–6
   PubMed Web of Science ®Google Scholar
• Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543–51
   PubMed Web of Science ®Google Scholar
• Brinton LA, Felix AS. Menopausal hormone therapy and risk of endometrial cancer. J Steroid Biochem Mol Biol 2014;142:83–9
   PubMed Web of Science ®Google Scholar
• Jaakkola S, Lyytinen HK, Dyba T, Ylikorkala O, Pukkala E. Endometrial cancer associated with various forms of postmenopausal hormone therapy: a case control study. Int J Cancer 2011;128:1644–51
   PubMed Web of Science ®Google Scholar
• Mørch LS, Kjær SK, Keiding N, Løkkegaard E, Lidegaard Ø. The influence of hormone therapies on type I and II endometrial cancer: A nationwide cohort study. Int J Cancer 2016;138:1506–15
   PubMed Web of Science ®Google Scholar
• Trabert B, Wentzensen N, Yang HP, et al. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? Int J Cancer 2013;132:417–26
   PubMed Web of Science ®Google Scholar
• Phipps AI, Doherty JA, Voigt LF, et al. Long-term use of continuous-combined estrogen-progestin hormone therapy and risk of endometrial cancer. Cancer Causes Control 2011;22:1639–46
   PubMed Web of Science ®Google Scholar
• Doherty JA, Cushing-Haugen KL, Saltzman BS, et al. Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. Am J Obstet Gynecol 2007;197:12–14
   PubMed Web of Science ®Google Scholar
• Anderson J, Peck E, Clark S. Estrogen-induced uterine responses and growth: relationship to receptor estrogen binding by uterine nuclei. Endocrinology 1975;96:160–7
   PubMed Web of Science ®Google Scholar
• Englund D, Johansson E. Endometrial effect of oral estriol treatment in postmenopausal women. Acta Obstet Gynecol Scand 1980;59:449–51
   PubMed Web of Science ®Google Scholar
• Granberg S, Eurenius K, Lindgren R, Wilhelmsson L. The effects of oral estriol on the endometrium in postmenopausal women. Maturitas 2002;42:149–56
   PubMed Web of Science ®Google Scholar
• Weiderpass E, Baron JA, Adami H-O, et al. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet 1999;353:1824–8
   PubMed Web of Science ®Google Scholar
• Sood R, Warndahl RA, Schroeder DR, et al. Bioidentical compounded hormones: a pharmacokinetic evaluation in a randomized clinical trial. Maturitas 2013;74:375–82
   PubMed Web of Science ®Google Scholar
• Eden JA, Hacker NF, Fortune M. Three cases of endometrial cancer associated with “bioidentical” hormone replacement therapy. Med J Aust 2007;187:244–5
   PubMed Web of Science ®Google Scholar
• Jessel R, Nachtigall M, Nachtigall L. Two cases of endometrial adenocarcinoma in postmenopausal women on bioidentical hormone replacementtherapy. Menopause 2009;16:1247 (poster 23)
   Google Scholar
• Davis R, Batur P, Thacker HL. Risks and effectiveness of compounded bioidentical hormone therapy: a case series. J Womens Health (Larchmt) 2014;23:642–8
   PubMed Web of Science ®Google Scholar
• Writing Group for the PEPI trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1996;275:370–5
   PubMed Web of Science ®Google Scholar
• Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med 2014;161:249–60
   PubMed Web of Science ®Google Scholar
• Darj E, Nilsson S, Axelsson O, Hellberg D. Clinical and endometrial effects of oestradiol and progesterone in post-menopausal women. Maturitas 1991;13:109–15
   PubMed Web of Science ®Google Scholar
• Moyer D, de Lignières B, Driguez P, Pez J. Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes. Fertil Steril 1993;59:992–7
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ. Treatment of postmenopausal women with topical progesterone creams and gels: are they effective? Climacteric 2014;17(Suppl 2):8–11
   PubMed Web of Science ®Google Scholar
• Allen NE, Tsilidis KK, Key TJ, et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation into cancer and nutrition. Am J Epidemiol 2010;172:1394–403
   PubMed Web of Science ®Google Scholar
• Gompel A, Santen RJ. Hormone therapy and breast cancer risk 10 years after the WHI. Climacteric 2012;15:241–9
   PubMed Web of Science ®Google Scholar
• Sjögren L, Mørch L, Lokkegaard E. Hormone replacement therapy and the risk of endometrial cancer: a systematic review. Maturitas 2016;91:25–35
   PubMed Web of Science ®Google Scholar
• Stute P, Neulen J, Wildt L. The impact of micronized progesterone on the endometrium: a systematic review. Climacteric 2016;19:316–28
   PubMed Web of Science ®Google Scholar
• Du J, Sanchez P, Kim L, Azen C. Percutaneous progesterone delivery via cream or gel application in postmenopausal women: a randomized cross-over study of progesterone levels in serum, whole blood, saliva, and capillary blood. Menopause 2013;20:1–7
   PubMed Web of Science ®Google Scholar
• Wren BG, McFarland K, Edwards L, et al. Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women. Climacteric 2000;3:155–60
   PubMedGoogle Scholar
• Gambrell R. Progesterone skin cream and measurements of absorption. Menopause 2003;10:2–3
   Web of Science ®Google Scholar
• Gaudard A, Silva D, Souza S, Puga M, et al. Bioidentical hormones for women with vasomotor symptoms. Cochrane Database Syst Rev 2016;8:1–103
   Google Scholar
• Elraiyah T, Sonbol MB, Wang Z, et al. Clinical review: The benefits and harms of systemic dehydroepiandrosterone (DHEA) in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. J Clin Endocrinol Metab 2014;99:3536–42
   PubMed Web of Science ®Google Scholar
• Davis SR, Panjari M, Stanczyk FZ. Clinical review: DHEA replacement for postmenopausal women. J Clin Endocrinol Metab 2011;96:1642–53
   PubMed Web of Science ®Google Scholar
• Davis SR, Shah SM, McKenzie DP, Kulkarni J, Davison SL, Bell RJ. Dehydroepiandrosterone sulfate levels are associated with more favorable cognitive function in women. J Clin Endocrinol Metab 2008;93:801–8
   PubMed Web of Science ®Google Scholar
• Shufelt C, Bretsky P, Almeida CM, et al. DHEA-S levels and cardiovascular disease mortality in postmenopausal women: results from the National Institutes of Health, National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women’s Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab 2010;95:4985–92
   PubMed Web of Science ®Google Scholar
• Davis SR, Worsley R. Androgen treatment of postmenopausal women. J Steroid Biochem Mol Biol 2014;142:107–14
   PubMed Web of Science ®Google Scholar
• Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2014;99:3489–510
   PubMed Web of Science ®Google Scholar
• Richardson M. Bioidentical hormone therapy: a challenge for the menopause clinician. Menopause 2016;23:353–4
   PubMed Web of Science ®Google Scholar
• Santoro N, Braunstein GD, Butts CL, Martin KA, McDermott M, Pinkerton JV. Compounded bioidentical hormones in endocrinology practice: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2016;101:1318–43
   PubMed Web of Science ®Google Scholar